Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Hepatology (Baltimore, Md.)|March 8, 2000
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis BA Erhardt, U Reineke, D Blondin, et al.
Digestive Diseases and Sciences|May 2, 2001
Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis BT Heintges, W Petry, M Kaldewey, et al.
Hepatology (Baltimore, Md.)|November 26, 1998
Prognosis of chronic hepatitis C: results of a large, prospective cohort studyC Niederau, S Lange, T Heintges, et al.
Human Gene Therapy|May 8, 2001
Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in miceL Mohr, S K Yoon, S J Eastman, et al.
Hepatology (Baltimore, Md.)|August 2, 2001
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis CK L Lindsay, C Trepo, T Heintges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2012
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306S Stintzing, L Fischer von Weikersthal, T Decker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)J W Holch, S Held, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)J W Holch, I Ricard, S Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studyS Stintzing, L Miller-Phillips, D P Modest, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)D P Modest, I Ricard, S Stintzing, et al.
Pageof 5